| Property | Value | [@hollingworth2011]
|----------|-------| [@kim2019]
| Gene Symbol | ABCA7 | [@aikawa2018]
| Full Name | ATP-Binding Cassette Transporter A7 | [@klein2020]
| Chromosomal Location | 19p13.3 | [@vasquez2020]
| NCBI Gene ID | 10347 | [@satoh2015]
| OMIM ID | 605414 | [@chan2018]
| Ensembl ID | ENSG00000064687 | [@fu2021]
| UniProt ID | Q9NP71 | [@reitz2020]
| Encoded Protein | ATP-binding cassette subfamily A member 7 | [@sassi2018]
| Associated Diseases | Alzheimer's disease, Spastic Paraplegia | [@nordestgaard2017]
ABCA7 is a human gene whose product aBCA7** encodes ATP-binding cassette transporter A7, a member of the ABC transporter family. ABCA7 is primarily expressed in immune cells and the brain, where it plays important roles in lipid transport and cellular homeostasis. Variants in ABCA7 have been implicated in Alzheimer's Disease (AD), Spastic Paraplegia. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
ABCA7 encodes ATP-binding cassette transporter A7, a member of the ABC transporter family. ABCA7 is primarily expressed in immune cells and the brain, where it plays important roles in lipid transport and cellular homeostasis.
Key normal physiological functions include:
The protein contains:
ABCA7 is a significant genetic risk factor for late-onset Alzheimer's disease:
Pathogenic mechanisms linking ABCA7 to AD:
Rare ABCA7 variants are associated with hereditary spastic paraplegia:
ABCA7 is expressed primarily in immune cells and brain:
In the brain, ABCA7 is particularly important in:
ABCA7 (ATP-Binding Cassette Transporter A7) shows microglial-enriched expression:
Single-cell RNA-seq data from the Allen Brain Atlas shows:
| Region | Expression Level | Data Source |
|---|---|---|
| Cortex | Medium-High | Human MTG |
| Hippocampus | Medium | Mouse Brain |
| White matter | High | Mouse Brain |
| Cerebellum | Low | Mouse Brain |
ABCA7 expression data available from the Allen Brain Atlas:
ABCA7 is a member of the ATP-binding cassette (ABC) transporter superfamily, specifically the A subfamily (ABCA). The protein is composed of several functional domains that enable its role in lipid transport:
| Domain | Location | Function |
|---|---|---|
| Nucleotide-Binding Domain 1 (NBD1) | N-terminal | ATP hydrolysis provides energy for transport |
| Nucleotide-Binding Domain 2 (NBD2) | C-terminal | ATP hydrolysis provides energy for transport |
| Transmembrane Domain 1 (TMD1) | Middle | Forms the translocation pore |
| Transmembrane Domain 2 (TMD2) | Middle | Forms the translocation pore |
| Regulatory Domain | Between NBDs | Controls transport activity |
The two NBDs each contain the characteristic Walker A (GXXXXGKST) and Walker B (hhhhDE) motifs, as well as the ABC signature (LSGGQ) motif. These domains work in concert to bind and hydrolyze ATP, coupling this energy to the conformational changes required for lipid translocation across cellular membranes.
The transmembrane domains consist of 12 α-helices that span the lipid bilayer, forming a channel through which lipids are transported. The substrate-binding site is thought to be located within the transmembrane domains, with specificity for various lipid species including phospholipids, cholesterol, and sphingolipids.
ABCA7 operates as an active transporter, using the energy from ATP hydrolysis to move lipids across cellular membranes against concentration gradients. The transport cycle involves several key steps:
ABCA7 functions as a homodimer, with two ABCA7 proteins forming a functional transporter. The dimerization is stabilized by interactions between the NBDs and by disulfide bonds in the extracellular domains.
One of the critical functions of ABCA7 is facilitating lipid efflux to apolipoprotein E (ApoE), similar to the related transporter ABCA1[@vasquez2020]. This process is essential for:
The cooperation between ABCA7 and ABCA1 in ApoE lipidation suggests some functional redundancy, but ABCA7 has unique roles in brain-specific lipid homeostasis.
Genome-wide association studies (GWAS) have identified multiple common variants in ABCA7 that influence AD risk[@hollingworth2011]:
| Variant | Position | Risk Allele | Odds Ratio | Effect |
|---|---|---|---|---|
| rs3764650 | Intron | G | 1.23 | Increased risk |
| rs4149268 | Intron | A | 1.15 | Increased risk |
| rs5987340 | Intron | G | 1.10 | Increased risk |
These variants are primarily located in intronic regions and are thought to affect ABCA7 expression or splicing rather than protein function.
Rare loss-of-function variants in ABCA7 have a stronger effect on AD risk[@williams2019]:
The effect of ABCA7 variants varies by ancestry:
ABCA7 is highly expressed in microglia, particularly in disease-associated microglia (DAM)[@kim2019]:
ABCA7 plays a critical role in microglial phagocytosis[@stewart2021]:
In ABCA7-deficient microglia:
ABCA7 modulates neuroinflammation through lipid-mediated signaling:
ABCA7-deficient mice recapitulate several features of AD risk[@liu2022]:
Restoring ABCA7 expression in knockout mice:
These studies support ABCA7 as a therapeutic target.
ABCA7 participates in a network of interactions relevant to AD:
| Interactor | Interaction Type | Functional Consequence |
|---|---|---|
| ApoE | Lipid transfer | Aβ clearance |
| ABCA1 | Functional cooperation | Redundant lipid transport |
| TREM2 | Pathway intersection | Microglial phagocytosis |
| CD33 | Antagonistic regulation | Phagocytosis balance |
| LDLR | Lipid binding | Cholesterol homeostasis |
| RAB proteins | Vesicle trafficking | Intracellular transport |
Given its role in AD pathogenesis, ABCA7 represents a promising therapeutic target:
| Strategy | Approach | Development Status |
|---|---|---|
| Gene therapy | Viral delivery of functional ABCA7 | Preclinical |
| Small molecule activators | Enhance ABCA7 expression/activity | Discovery phase |
| Protein replacement | Direct ABCA7 protein delivery | Research stage |
| Modulator compounds | Allosteric modulation | Lead optimization |
Several challenges face ABCA7-targeted therapies:
ABCA7 has potential as a biomarker:
ABCA7 expression is subject to epigenetic regulation[@wang2023]:
This epigenetic dysregulation provides a mechanistic link between environmental risk factors and ABCA7 function in AD.
ABCA7 and ABCA1 are closely related transporters with both overlapping and distinct functions:
| Feature | ABCA7 | ABCA1 |
|---|---|---|
| Primary expression | Brain (microglia), immune cells | Liver, peripheral cells |
| ApoE lipidation | Yes | Yes |
| Cholesterol efflux | Moderate | High |
| AD risk association | Strong | None |
| Therapeutic potential | High | Limited for AD |
The differential AD risk association suggests unique functions of ABCA7 in brain lipid homeostasis that are not compensated by ABCA1.
Key questions remain about ABCA7 in AD:
Answering these questions will advance our understanding of ABCA7 in AD pathogenesis and inform therapeutic development.
ABCA7 genetic testing has several clinical applications:
ABCA7-targeted therapies offer disease-modifying potential:
ABCA7 has potential as a biomarker:
Several challenges face ABCA7-targeted approaches:
ABCA7 interacts with multiple AD genetic risk factors:
| Gene | Interaction Type | Mechanism |
|---|---|---|
| APOE | Synergistic | Combined effects on lipid metabolism |
| TREM2 | Additive | Microglial phagocytosis pathways |
| CD33 | Antagonistic | Opposing effects on phagocytosis |
| ABCA1 | Complementary | Overlapping lipid transport functions |
| CLU | Synergistic | Chaperone-mediated lipid transport |
The network of interactions suggests that targeting ABCA7 may have broad effects on AD pathogenesis.
ABCA7 represents a significant genetic risk factor for late-onset Alzheimer's disease. Key points include:
Continued research on ABCA7 will advance our understanding of AD pathogenesis and develop novel therapeutic strategies.
ABCA7 research exemplifies the intersection of lipid metabolism, neuroinflammation, and neurodegeneration. The identification of ABCA7 as an AD risk gene has opened new avenues for understanding microglial biology and developing therapeutic interventions. Future studies will likely reveal additional mechanisms by which ABCA7 influences AD pathogenesis and identify novel therapeutic targets within the ABCA7 pathway.